The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
Stefano Kette(Ospedale di Cattinara), Barbara Ruaro(University of Trieste), Maria Chianese(University of Trieste), Michael Hughes(Universitat Autònoma de Barcelona), Lucrezia Mondini(University of Trieste), Marco Confalonieri(Ospedale di Cattinara), Anna De Nes(University of Trieste), Alessandra Galantino(University of Trieste), Nicolò Reccardini(University of Trieste), Salvatore Fabio Nicolosi(University of Trieste), Paola Confalonieri(University of Trieste), Francesco Salton(University of Trieste), Maria Chernovsky(University of Trieste), Marta Maggisano(University of Trieste), Darina Angoni(University of Trieste), Alessia Giovanna Andrisano, Marco Mari(University of Trieste), Andrea Salotti(University of Trieste)
Cited by 6
Related Papers
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
|Journal of Clinical Oncology|2014|777
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
|Pharmaceuticals|2024|86
miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation
|ERJ Open Research|2019|59
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
|Cell Death and Disease|2013|57
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
|British Journal of Cancer|2010|49